The most consequential thing Long Island has produced this decade may turn out to be a molecule. It has an unlovely name, ART26.12, it was designed in a chemistry lab in Stony Brook, and it is an attempt at something the pharmaceutical industry has been failing at for thirty years: a painkiller that works on serious nerve pain without being an opioid.

What was announced this month

On July 1, Artelo Biosciences, the company developing the compound, released new preclinical results extending ART26.12 into a second kind of pain. The work was presented by Martin Kaczocha, a professor of anesthesiology at Stony Brook University, at the International Cannabinoid Research Society's annual symposium in Dijon, France, under the title "Inhibition of Fatty Acid Binding Protein 5 Alleviates Neuropathic Pain Following Spinal Cord Injury in Mice."

In a validated mouse model of spinal cord injury pain, blocking the protein the drug targets did four things: it reduced the exaggerated response to touch that defines nerve pain, it cut spontaneous pain behavior, it calmed overexcited pain-sensing neurons, and it worked when given by mouth. That last item is not a footnote. A great many promising analgesics work beautifully by injection into a laboratory animal and are useless as a pill.

"These data support continued exploration of FABP5 inhibition as a novel analgesic strategy," Kaczocha said.

The relevant scale: roughly 90 percent of people with a spinal cord injury live with chronic pain, and in up to 60 percent of them it is neuropathic pain that does not respond well to anything currently available.

The idea behind the molecule

Most pain drugs either dull the whole nervous system or shut down inflammation. ART26.12 tries a third route.

The body makes its own cannabinoid-like signaling molecules, and among their jobs is turning pain signaling down. They are also cleared away quickly, which limits how much relief they provide. Fatty acid binding protein 5, or FABP5, is part of the machinery that moves those molecules toward being broken down.

Block FABP5 and you do not introduce a foreign painkiller. You let the body's own pain-dampening signals persist longer where they are already being produced. And because ART26.12 is designed to act peripherally, out at the nerves rather than in the brain, the intent is to avoid the sedation, cognitive fog and dependence that make opioids what they are.

It is believed to be the first selective FABP5 inhibitor ever to reach clinical trials, which means the concept itself is being tested for the first time in people, not just this particular version of it.

Why chemotherapy patients first

The initial target is chemotherapy-induced peripheral neuropathy, the burning, numbness and electric pain in hands and feet that follows certain cancer treatments. By Stony Brook's own account it affects roughly 40 percent of people undergoing chemotherapy.

It is a brutal and under-discussed problem. There is very little that treats it well. And it drives a decision no one should have to make, in which patients reduce or stop cancer treatment that is working because they cannot tolerate what it is doing to their nerves. A drug that made that side effect manageable would not just relieve pain. It would let people finish chemotherapy.

Two Long Island labs, one compound

The compound came from a collaboration between two Stony Brook researchers working from opposite directions. Distinguished Professor Iwao Ojima, a synthetic chemist, invented it. Kaczocha, an anesthesiology researcher, worked on the biology of why it should help. The resulting library of FABP inhibitors was exclusively licensed to Artelo with global rights.

That is the university-research pipeline functioning as it is supposed to and rarely does. Almost all of it stalls: a compound works in mice, the papers get published, the patent sits, and nothing reaches a person. This one has an FDA-cleared investigational new drug application and a Phase 1 study running at a clinical pharmacology unit in San Antonio, where the first cohort of volunteers was completed and the company has since raised private money specifically to push it forward.

Where it actually stands

Now the honest part, because non-opioid painkiller headlines have a long history of overpromising.

A Phase 1 trial is not a test of whether a drug relieves pain. It is a test of whether healthy volunteers tolerate it and how the body processes it. The pain data so far is from mice. Patient trials are anticipated in 2027, and only those will begin to answer the question everyone actually cares about.

Most drugs that get this far still fail. The graveyard of promising non-opioid analgesics is genuinely enormous, and nerve pain in particular has defeated an impressive number of well-funded programs, because the mouse models are imperfect and human pain is a subjective thing measured through a haze of placebo response.

So the correct level of enthusiasm is: this is a real, novel mechanism, invented here, that has cleared regulatory review and entered human testing, with fresh evidence this month that it may reach a second population of patients. That is meaningful and it is not a cure yet.

Why it matters here

Long Island's economy is usually discussed in terms of health care employment, and there is a lot of it. Health care has been carrying regional job growth for years. But employment in hospitals and offices is the visible half. The other half is research, and research is the part that occasionally produces something that leaves the Island entirely and turns up in a clinic in another country.

Stony Brook is where that happens here, alongside a hospital build-out that is reshaping where Long Islanders get care. A molecule designed in a lab on Nicolls Road, tested in Texas, and presented in France is a fair picture of what a research university is actually for.

If ART26.12 works, the story will be told as a win for pain medicine and for the effort to find something that treats severe pain without the thing that caused the opioid crisis. It will also, quietly, be a Long Island story.